RCT 234 mild-moderate COVID-19 patients with 171 treated with proxalutamide, showing significantly faster viral clearance and recovery.
Cadegiani et al., 2/22/2021, Double Blind Randomized Controlled Trial, Brazil, South America, peer-reviewed, 8 authors.
risk of no virological cure, 92.1% lower, RR 0.08, p < 0.001, treatment 7 of 171 (4.1%), control 34 of 66 (51.5%), day 7, not including loss of taste or smell.
risk of no recovery, 76.8% lower, RR 0.23, p < 0.001, treatment 30 of 171 (17.5%), control 50 of 66 (75.8%), day 7, including loss of taste or smell.
recovery time, 85.0% lower, relative time 0.15, treatment 171, control 66, day 7, not including loss of taste or smell.
recovery time, 80.7% lower, relative time 0.19, treatment 171, control 66, day 7, including loss of taste or smell.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.